AiCure

Actavis

Actavis to acquire Allergan for $66 billion

Monday, November 17, 2014 02:22 PM

Dublin-based Actavis, a global, integrated, specialty pharmaceutical company has announced it will acquire Allergan, a multi-specialty healthcare company based in Irvine, Calif., for approximately $66 billion, or $219 per share.

More... »


FDA accepts Actavis’ sNDA for Saphris for bipolar I disorder in pediatric patients

Thursday, November 13, 2014 02:35 PM

The FDA has accepted for filing Actavis' supplemental New Drug Application (sNDA) for Saphris (asenapine) for the acute treatment of manic or mixed episodes associated with bipolar I disorder in pediatric patients 10 to 17 years of age. Actavis' sNDA for Saphris has been granted priority review status by the FDA.

More... »


Actavis signs option to acquire Rhythm subsidiary

Thursday, October 23, 2014 01:08 PM

Actavis, a Dublin, Ireland-based global specialty pharmaceutical company, has been granted an exclusive option to acquire Rhythm subsidiary Rhythm Health, a Boston, Mass.-based biopharmaceutical company developing relamorelin (RM-131), a peptide ghrelin agonist, for the treatment of diabetic gastroparesis and other GI functional disorders.

More... »

Actavis to acquire Durata Therapeutics

Monday, October 6, 2014 04:00 PM

Actavis, a global specialty pharmaceutical company based in Dublin, Ireland, and Durata Therapeutics, an innovative pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses, headquartered in Chicago, Ill., have entered into a definitive merger agreement.

More... »

Actavis completes acquisition of Furiex Pharmaceuticals

Friday, July 4, 2014 08:00 AM

Forest Laboratories, a subsidiary of Actavis, has successfully completed its acquisition of Furiex Pharmaceuticals in an all-cash transaction valued at approximately $1.1 billion, and up to approximately $360 million in a Contingent Value Right (CVR) that may be payable based on the status of eluxadoline, Furiex's lead product, as a controlled drug following approval.

More... »

Actavis completes Forest Laboratories acquisition

Tuesday, July 1, 2014 10:50 AM

Dublin-based Actavis has completed its acquisition of Forest Laboratories in a cash and equity transaction valued at approximately $28 billion. The combination creates a specialty pharmaceutical company with annual revenues of more than $15 billion anticipated for 2015.

More... »

Forest Labs’ $1.46 billion acquisition of Furiex strengthens GI business

Tuesday, April 29, 2014 03:24 PM

The pharmaceutical industry’s shopping spree for specific disease expertise or scale continued this week as Forest Laboratories announced plans to acquire Furiex Pharmaceuticals for up to $1.46 billion, including milestone payments.

More... »

Actavis launches Asia Pacific regional headquarters in Singapore

Friday, April 4, 2014 12:01 PM

Actavis, a global specialty pharmaceutical company, has opened its new regional office in Singapore, which will serve as the headquarters for the company's Asia Pacific and Africa (APACA) region.

More... »

Actavis to acquire Forest Laboratories for $25 billion

Tuesday, February 18, 2014 10:39 AM

Dublin-based Actavis has agreed to acquire Forest Laboratories of New York for a combination of cash and equity valued at approximately $25 billion.

More... »

Aurobindo acquires commercial operations in seven countries from Actavis

Monday, January 20, 2014 11:59 AM

Aurobindo Pharma, a Hyderabad, India-based manufacturer of generic pharmaceuticals and active pharmaceutical ingredients, has signed a binding offer to acquire commercial operations in seven Western European countries from Actavis, a Dublin, Ireland-based global, integrated specialty pharmaceutical company. Closing of the transaction is conditional on certain antitrust approvals and completion of employee consultation processes.

More... »

CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

November 24

Tufts CSDD’s $2.6 billion price tag to develop and bring a new drug to market raises questions, criticisms

Medidata joins GlaxoSmithKline in study to evaluate the impact of wearing mobile devices in clinical trials

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs